Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteThe headline that Seattle biotech Deverra Therapeutics was raising cash describes a September 2023 financing, not a confirmed current offering. GeekWire reported then that the company had raised about $2.4 million through debt and warrants. Deverra’s latest financial disclosure located here, its annual report dated May 1, 2026, describes severe liquidity constraints and plans to seek additional capital, but does not establish that an offering is currently open or disclose terms.
What the 2023 fundraising headline means
On September 19, 2023, GeekWire reported that a new SEC filing showed Deverra had raised about $2.4 million through debt and warrants. That figure belongs to the 2023 financing report. It should not be read as a current raise, a current cash balance, or evidence that investors can presently buy into an offering.
Deverra’s annual report, dated May 1, 2026 and filed May 6, 2026, says the company planned to raise additional capital and pursue other options. It does not establish whether a financing is currently available or specify offering terms. Anyone evaluating the company as an investment should consult current SEC filings and offering documents rather than rely on the older headline.
What Deverra is developing
Deverra is a Seattle clinical-stage biotechnology company developing allogeneic, or donor-derived, cellular immunotherapies. The company says its platform uses a proprietary Notch-mediated stem-cell expansion and directed-differentiation process licensed from Fred Hutch Cancer Center. It uses donor umbilical cord blood cells to produce immune and progenitor cells intended for use without matching each donor to a patient. These are descriptions of Deverra’s platform and intended approach, not proof of superiority or evidence that its products are available treatments. More detail is on the company’s overview page.
#1 Best Overall
- 【FILTER IN SECONDS】Filtration can be a pain, taking hours using gravity alone. Our lab vacuum pump, which works at 10L/min, can accomplish the same job in seconds - even with highly viscous liquids. The vacuum pump can save hours in the lab and let you run more experiments - or produce more product. Many of our customers use our lab filtration pump for essential oils, e-juice, home-brewing and more
- 【OIL FREE】Many other pumps need their oil changed after only 12 hours of use. And cheaper models are also notoriously weak and unreliable. The LABFISH vacuum pump uses a powerful, 0.075Mpa oilless small diaphragm pump, which means it isn’t messy and doesn’t need regular maintenance. The pump can pull a vacuum strong enough for most lab or industrial work
- 【ANTI-SLIP】The unique base design, containing four special rubber anti-slip pads, can be steadily fixed on the workbench to prevent the machine from shaking and run more quietly and steadily
- 【COMPACT DESIGN】The small vacuum pump is compact and easy to store when not in use. It is built with sturdy lab-quality materials meant to last for years. The oilless design also guarantees that oil from the pump won’t contaminate your work - a risk in many pumps
- 【APPLICATIONS】Can be used wildly in aerator, nitrogen blower, solid phase extractor, thin layer color developing spray, solvent filter, air sampler and other vacuum pressure need.There are more uses in life. When you need to use a vacuum storage bag with a valve to store food or items, you will find it very convenient
How its programs differ
| Program | Stage and intended use | Development or licensing status |
|---|---|---|
| Dilanubicel | Lead investigational hematopoietic stem and progenitor cell therapy; intended as an adjunct to standard chemotherapy for newly diagnosed acute myeloid leukemia (AML). | Deverra says it is seeking a pharmaceutical partner to support commercialization. |
| DVX201 | Unmodified natural killer (NK) cell product; Deverra says it was safely dosed in two Phase 1 trials. | Licensed to Coeptis Therapeutics for specified fields, including viral infections and relapsed or refractory AML or high-risk myelodysplastic syndrome. |
| Engineered NK and myeloid-cell platforms | Preclinical or IND-enabling programs for hematologic malignancies and solid tumors, according to the company. | Under a late-2025 exclusive license, Seattle Children’s assumed development and manufacturing responsibilities for certain preclinical assets. |
Program descriptions and stages are based on Deverra’s company website and program pages, and the company’s 2025 annual report. Licensing or a development partnership does not mean a therapy is approved or commercially available.
Dilanubicel remains investigational
Deverra says a global randomized Phase 2 trial found a statistically significant increase in remission rates when dilanubicel was added to standard chemotherapy compared with chemotherapy alone. The company’s 2025 annual report also says the program has FDA Regenerative Medicine Advanced Therapy (RMAT) designation. RMAT is a designation, not FDA approval, and does not guarantee approval. The materials cited here do not establish the trial’s endpoint definitions or effect sizes, so the company’s summary should not be treated as a complete account of the clinical evidence.
Rank #2
- Ultra-Low Temperature Performance: An efficient single-stage compressor for the ultra-low temperature freezer enables fast cooling and energy saving. Temperature range from -40℉ to -123℉ provides flexible storage for sensitive lab samples
- Precise ±0.1°C Microcomputer Control: The lab freezer is microprocessor-controlled with an advanced digital interface for real-time monitoring and ultra-precise temperature adjustment, critical for preserving sensitive biological samples
- Customizable Smart Alarm System: Users can set custom temperature thresholds. Audible and visual alarms safeguard critical samples. The ultra low temp freezer includes keyed lock for physical security against unauthorized access
- Energy-saving Design: Our 25L lab cryogenic freezer features low power consumption (230W, 2.8 kWh/day), 304 stainless steel interior, premium refrigerant, and lightweight at 63.93 lbs for flexible placement
- Wide Applications: Ideal for precise scientific research, long-term sample storage, specialized material testing, and advanced biotech studies, meeting diverse lab needs
Deverra says it is seeking a pharmaceutical partner to enable commercialization. That is a stated business objective, not an announced commercialization agreement or a forecast of when the therapy might reach patients.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the latest financial disclosure says
In its annual report dated May 1, 2026, Deverra reported approximately $1,612 in cash and approximately $4.5 million in negative working capital as of December 31, 2025. These are dated company-reported figures, not a current cash balance. The filing reported revenue of $696,727 in 2025, down from $3.9 million in 2024, attributing the decrease to the completion of two Washington State grants and termination of a shared-services agreement with Coeptis.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Rank #3
- 2000 W ULTRASONIC HOMOGENIZER, 1000 to 3000 mL: A 2000 W lab ultrasonic homogenizer and cell disruptor processes 1000 to 3000 mL samples for mixing, emulsifying, homogenizing, dispersing, and particle-size reduction
- ADJUSTABLE 0 TO 100% POWER, PULSE MODE: Set ultrasonic output from 0 to 100% and use variable pulse mode to match delicate or tough samples, with automatic amplitude control for consistent results
- LCD DISPLAY, PROGRAMMABLE TIMER: A clear LCD shows all settings at a glance, with easy programming and up to 99 hours of total working-time control for hands-free, precise, repeatable ultrasonic runs
- TEMPERATURE PROTECTION, QUIET CHAMBER: A temperature indicator helps prevent overheating and a sound-abating chamber cuts cavitation noise for safe, comfortable benchtop operation
- DURABLE TITANIUM ALLOY PROBES: Engineered for longevity and biocompatibility, our high-efficiency probes are corrosion-resistant and lightweight. Perfect for cell disruption, dispersion, and emulsification in demanding lab environments
The same filing describes recurring losses and negative operating cash flow, which Deverra expects to continue in the near term. The company said it planned to address working capital through expense management, divestiture of development assets, and raising capital through equity or debt. It also said these conditions raise substantial doubt about its ability to continue as a going concern for twelve months from the report’s issuance date. These are the company’s disclosures and assessment; the filing does not establish what its cash position is after year-end 2025.
Quick Recap
Best Value
- Ultra-Low Temperature Performance: An efficient single-stage compressor for the ultra-low temperature freezer enables fast cooling and energy saving. Temperature range from -40℉ to -123℉ provides flexible storage for sensitive lab samples
- Precise ±0.1°C Microcomputer Control: The lab freezer is microprocessor-controlled with an advanced digital interface for real-time monitoring and ultra-precise temperature adjustment, critical for preserving sensitive biological samples
- Customizable Smart Alarm System: Users can set custom temperature thresholds. Audible and visual alarms safeguard critical samples. The ultra low temp freezer includes keyed lock for physical security against unauthorized access
- Large capacity Design : Our 58L lab cryogenic freezer features premium 304 stainless steel, easy to clean. It is equipped with fast cooling single-stage compressor and all-copper refrigeration system for stable low temps
- Wide Applications: Ideal for precise scientific research, long-term sample storage, specialized material testing, and advanced biotech studies, meeting diverse lab needs
Rank #4
- High Accuracy and Precision: Each pipette is calibrated in accordance with ISO8655 and each micro pipette is supplied with an individual test certificate.
- Wide Tip Compatibility: It is compatible with most universal tip brands covering full volume range
- Humanization: ergonomic design, lightweight plunger force can reduce repetitive strain injury. The digital display can clearly read the volume setting. Tip ejector for easy and fast needle tip replacement.
- Easy to calibrate: Each pipette is fully calibrated before shipment. It's easy to calibrate for the users with the tools and instruction supplied.
- 1 Year Guarantee and Satisfied Service: we are manufacturer which has more than 20 years experience in the field of lab products. . Any quality problem, we will provide free replacement
What a reader should take from the story
- For investors: The 2023 financing headline is historical. The 2026 annual report indicates reliance on additional funding or other measures, but does not document an open offering or its terms.
- For patients and caregivers: Dilanubicel and the other described cell products are investigational or preclinical, not established treatment options on the evidence cited here. Discuss AML care with a qualified oncology team.
- For readers tracking the company: Separate Deverra’s lead program from assets licensed to partners, and distinguish company-reported trial summaries from independently detailed clinical results.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
